TrialNet: University of Florida Clinical Center and Network

描述(由申请人提供)：佛罗里达大学是DPT-1和国际组成的糖尿病试验网络(类型1糖尿病试验网络)的创始成员之一，为试验网络和类型1糖尿病(T1D)做出了重大和重要的贡献，它作为表现最好的临床中心之一参与其中。TrialNet的主要目标是通过测试旨在减少细胞破坏和/或提高细胞存活率的干预措施，预防和/或延缓T1D在疾病风险人群中的发展。佛罗里达大学寻求继续作为临床中心作为TrialNet网络的一部分。NIH TrialNet RFA打算通过资助必要的基础设施来继续为高生产率中心提供支持，这些基础设施将能够对大量的T1D亲属进行筛查，以识别那些有临床疾病风险的人。继续成为TrialNet成员将使我们建立并非常成功的佛罗里达大学临床中心及其强大的附属网络能够继续支持受试者招募到研究中，提高试验表现、受试者保留和后续行动。事实上，我们的中心正准备通过其卓越的环境和具有成熟方法的创新研究人员继续探索未来预防和逆转T1D的工作，每个研究人员都致力于寻找预防/治愈疾病的方法，以及加强T1D临床试验的招募和保留。作为对这一RFA的回应，本申请描述：1)该机构对TrialNet和T1D领域的独特优势和贡献；2)确定和保持活跃的附属机构网络的持续和新颖的战略；3)招聘、拓展和协作计划；4)提高成本效率的战略；5)绩效监测；6)考虑联合IRB；7)未来T1D临床研究人员的发展；以及8)当前和未来5年预防T1D的潜在机遇和挑战。

DESCRIPTION (provided by applicant): The University of Florida, a founding member of the DPT-1 and the internationally constituted diabetes trial network (Type 1 Diabetes TrialNet), has made significant and important contributions to TrialNet and type 1 diabetes (T1D), where it participates as one of the top performing Clinical Centers. The primary goal of TrialNet is to prevent and/or delay the development of T1D in persons at risk for the disease by testing interventions targeted at decreasing ¿-cell destruction and/or enhancing ¿-cell survival. The University of Florida seeks to continue serving as a Clinical Center as part of the TrialNet network. The NIH TrialNet RFA intends to continue providing support for highly productive centers by funding the necessary infrastructure that would enable screening large numbers of T1D relatives so as to identify those at risk of clinical disease. Continuing TrialNet membership would enable our established and highly successful University of Florida Clinical Center and its strong Affiliate network to continue supporting subject recruitment into studies, enhancing trial performance, subject retention, and follow-up. Indeed, our Center is poised to continue the quest for the future prevention and reversal of T1D through its outstanding environment and innovative investigators with proven approaches, each dedicated to identifying a means to prevent/cure the disease as well as to enhance recruitment and retention for T1D clinical trials. In responding to this RFA, this application describes: 1) Unique strengths and contributions of the institution to TrialNet and the T1D field; 2) Ongoing and novel strategies to identify and maintain an active Affiliate network; 3) Recruitment, outreach, and collaboration plans; 4) Strategies to enhancing cost efficiency; 5) Performance monitoring; 6) Consideration of federated IRB; 7) Development of future T1D clinical researchers; and 8) Potential opportunities and challenges for the prevention of T1D currently and over the next 5 years.